Quinone reductase 2 as a promising target of melatonin therapeutic actions

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 3, 2016, Pages 303-317

  Boutin, Jean A ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

antioxidant; melatonin; melatonin receptors; quinone reductase 2; reactive oxygen species

Indexed keywords

MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; QUINONE REDUCTASE 2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; ANTIOXIDANT; NRH - QUINONE OXIDOREDUCTASE2;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOLOGICAL ACTIVITY; BRAIN DEVELOPMENT; CIRCADIAN RHYTHM; CRYSTALLIZATION; DRUG MECHANISM; ENZYME INHIBITION; EXCITOTOXICITY; GLUCOSE HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RELEASE; ISCHEMIC PRECONDITIONING; NONHUMAN; OXIDATIVE STRESS; PHYSIOLOGY; PROTEIN TARGETING; PUBLICATION; RATE CONSTANT; REVIEW; SEASONAL VARIATION; TESTOSTERONE SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIOXIDANTS; HUMANS; MELATONIN; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; QUINONE REDUCTASES; REACTIVE OXYGEN SPECIES;

EID: 84958035144     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1091882     Document Type: Review

References (169)

1. Lerner AB, Case JD, Takahashi Y, et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958;80:2587-8
2. Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 2005;26:412-19
3. Delagrange P, Atkinson J, Boutin JA, et al. Therapeutic perspectives for melatonin agonists and antagonists. J Neuroendocrinol 2003;15:442-8
4. Delagrange P, Boutin JA. Therapeutic potential of melatonin ligands. Chronobiol Int 2006;23:413-18
5. Jockers R, Maurice P, Boutin JA, Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: whats new? Br J Pharmacol 2008;154:1182-95
6. Lerner AB, Case JD, Mori W, Wright MR. Melatonin in peripheral nerve. Nature 1959;183:1821
7. Wurtman RJ, Axelrod J. The formation, metabolism, and physiologic effects of melatonin in mammals. Prog Brain Res 1965;10:520-9
8. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-80
9. Legros C, Chesneau D, Boutin JA, et al. Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions. J Neuroendocrinol 2014;26:151-63
10. Reiter RJ, Tan DX, Manchester LC, et al. Medical implications of melatonin: receptor-mediated and receptorindependent actions. Adv Med Sci 2007;52:11-28
11. Hardeland R, Reiter RJ, Poeggeler B, Tan DX. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993;17:347-57
12. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005;177:448-58
13. Rivara S, Pala D, Bedini A, Spadoni G. Therapeutic uses of melatonin and melatonin derivatives: A patent review (2012-2014). Expert Opin Ther Pat 2015;25:425-41
14. Shirayama Y, Takahashi M, Suzuki M, et al. Effects of add-on ramelteon on cognitive impairment in patients with schizophrenia: an open-label pilot trial. Clin Psychopharmacol Neurosci 2014;12:215-17
15. Carocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development. Clin Pharmacol 2014;6:127-37
16. Forman HJ, Augusto O, Brigelius-Flohe R, et al. Even free radicals should follow some rules: A guide to free radical research terminology and methodology. Free Radic Biol Med 2015;78:233-5
17. Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med 2014;66:24-35
18. Haag WR, Yao CCD. Rate constants for reaction of hydroxyl radicals with several drinking water contaminants. Environn Sci Technol 1992;26:1005-23
19. Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005;2:22
20. Cho EH, Koh PO. Proteomic identification of proteins differentially expressed by melatonin in hepatic ischemia-reperfusion injury. J Pineal Res 2010;49:349-55
21. Luchetti F, Canonico B, Betti M, et al. Melatonin signaling and cell protection function. FASEB J 2010;24:3603-24
22. Limon-Pacheco JH, Gonsebatt ME. The glutathione system and its regulation by neurohormone melatonin in the central nervous system. Cent Nerv Syst Agents Med Chem 2010;10:287-97
23. Szaroma W, Dziubek K. Changes in the amount of reduced glutathione and activity of antioxidant enzymes in chosen mouse organs influenced by zymosan and melatonin administration. Acta Biol Hung 2011;62:133-41
24. Chakravarty S, Rizvi SI. Day and Night GSH and mda levels in healthy adults and effects of different doses of melatonin on these parameters. Int J Cell Biol 2011;2011:404591
25. Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000;917:387-96
26. Vriend J, Reiter RJ. Melatonin and ubiquitin: what's the connection? Cell Mol Life Sci 2014;71:3409-18
27. Reybier K, Perio P, Ferry G, et al. Insights into the redox cycle of human quinone reductase 2. Free Radic Res 2011;45:1184-95
28. Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000;275:31311-17
29. Dufourny L, Levasseur A, Migaud M, et al. GPR50 is the mammalian ortholog of Mel1c: evidence of rapid evolution in mammals. BMC Evol Biol 2008;8:105
30. Carlberg C, Wiesenberg I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. J Pineal Res 1995;18:171-8
31. Lardone PJ, Guerrero JM, Fernandez-Santos JM, et al. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J Pineal Res 2011;51:454-62
32. Dai J, Ram PT, Yuan L, et al. Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin. Mol Cell Endocrinol 2001;176:111-20
33. Dong C, Yuan L, Dai J, et al. Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells. Steroids 2010;75:944-51
34. Acuna-Castroviejo D, Reiter RJ, Menendez-Pelaez A, et al. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res 1994;16:100-12
35. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13:1177-85
36. Reppert SM, Godson C, Mahle CD, et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: The Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995;92:8734-8
37. Audinot V, Bonnaud A, Grandcolas L, et al. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochem Pharmacol 2008;75:2007-19
38. Devavry S, Legros C, Brasseur C, et al. Molecular pharmacology of the mouse melatonin receptors MT(1) and MT(2). Eur J Pharmacol 2012;677:15-21
39. Coge F, Guenin SP, Fery I, et al. The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor. Br J Pharmacol 2009;158:1248-62
40. Mailliet F, Audinot V, Malpaux B, et al. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem Pharmacol 2004;67:667-77
41. Audinot V, Mailliet F, Lahaye-Brasseur C, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003;367:553-61
42. Barrett P, Bolborea M. Molecular pathways involved in seasonal body weight and reproductive responses governed by melatonin. J Pineal Res 2012;52:376-88
43. Dupre SM, Dardente H, Birnie MJ, et al. Evidence for RGS4 modulation of melatonin and thyrotrophin signalling pathways in the pars tuberalis. J Neuroendocrinol 2011;23:725-32
44. Zhao WJ, Zhang M, Miao Y, et al. Melatonin potentiates glycine currents through a PLC/PKC signalling pathway in rat retinal ganglion cells. J Physiol 2010;588:2605-19
45. Brydon L, Roka F, Petit L, et al. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol 1999;13:2025-38
46. Brydon L, Petit L, de Coppet P, et al. Polymorphism and signalling of melatonin receptors. Reprod Nutr Dev 1999;39:315-24
47. Kamal M, Gbahou F, Guillaume JL, et al. Convergence of Melatonin and 5-HT Signaling at MT2/5-HT2C Receptor Heteromers. J Biol Chem 2015;290(18):11537-46
48. Maurice P, Daulat AM, Turecek R, et al. Molecular organization and dynamics of the melatonin MT(1) receptor/RGS20/G (i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling. EMBO J 2010;29:3646-59
49. Maurice P, Daulat AM, Broussard C, et al. A generic approach for the purification of signaling complexes that specifically interact with the carboxylterminal domain of G protein-coupled receptors. Mol Cell Proteomics 2008;7:1556-69
50. Baba K, Benleulmi-Chaachoua A, Journe AS, et al. Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci Signal 2013;6:ra89
51. Zlotos DP, Jockers R, Cecon E, et al. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 2014;57:3161-85
52. Ferre S, Casado V, Devi LA, et al. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 2014;66:413-34
53. Mor M, Rivara S, Pala D, et al. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. Expert Opin Ther Pat 2010;20:1059-77
54. Bi W, Bi Y, Xue P, et al. Synthesis and characterization of novel indole derivatives reveal improved therapeutic agents for treatment of ischemia/reperfusion (I/R) injury. J Med Chem 2010;53:6763-7
55. Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol 2010;16:6087-97
56. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 1995;16:50-6
57. Paul P, Lahaye C, Delagrange P, et al. Characterization of 2-[125I] iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther 1999;290:334-40
58. Boutin JA. MT3: The third melatonin binding site. In: Acuna-Castroviejo D, Rustanova I, Escames G, editors. New developments in melatonin research. Nova Science Publishers; New York: NY: USA: 2013. p. 77-100
59. Tan DX, Manchester LC, Terron MP, et al. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 2007;43:317-20
60. Boutin JA, Marcheteau E, Hennig P, et al. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. J Pineal Res 2008;45:524-31
61. Calamini B, Santarsiero BD, Boutin JA, Mesecar AD. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J 2008;413:81-91
62. Mailliet F, Ferry G, Vella F, et al. Organs from mice deleted for NRH: quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett 2004;578:116-20
63. Boutin JA, Chatelain-Egger F, Vella F, et al. Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem Biol Interact 2005;151:213-28
64. Graves PR, Kwiek JJ, Fadden P, et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 2002;62:1364-72
65. Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry (Mosc) 2004;43:4538-47
66. Buryanovskyy L, Fu Y, Boyd M, et al. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004;43:11417-26.
67. Hsieh TC, Bennett DJ, Lee YS, et al. In silico and biochemical analyses identify quinone reductase 2 as a target of piceatannol. Curr Med Chem 2013;20:4195-202
68. Dufour M, Yan C, Siegel D, et al. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition. ChemBioChem 2011;12:1203-8
69. Boussard MF, Truche S, Rousseau-Rojas A, et al. New ligands at the melatonin binding site MT(3). Eur J Med Chem 2006;41:306-20
70. Pegan SD, Sturdy M, Ferry G, et al. X-ray structural studies of quinone reductase 2 nanomolar range inhibitors. Protein Sci 2011;20:1182-95
71. Benoit CE, Bastianetto S, Brouillette J, et al. Loss of quinone reductase 2 function selectively facilitates learning behaviors. J Neurosci 2010;30:12690-700
72. Janda E, Parafati M, Aprigliano S, et al. The antidote effect of quinone oxidoreductase 2 inhibitor against paraquat-induced toxicity in vitro and in vivo. Br J Pharmacol 2013;168:46-59
73. Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol Pharm Bull 2012;35:273-9
74. Bubenik GA, Blask DE, Brown GM, et al. Prospects of the clinical utilization of melatonin. Biol Signals Recept 1998;7:195-219
75. Devi V, Hashim OH, Jayapalan JJ, Subramanian P. Effect of melatonin with antioxidant status and circadian activity rhythm during hepatocarcinogenesis in mice. J Cancer Res Ther 2014;10:1040-4
76. Kang N, Koo J. Olfactory receptors in non-chemosensory tissues. BMB Rep 2012;45:612-22
77. Kang N, Kim H, Jae Y, et al. Olfactory marker protein expression is an indicator of olfactory receptor-associated events in non-olfactory tissues. PLoS One 2015;10:e0116097
78. Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther Adv Endocrinol Metab 2013;4:13-24
79. Tan DX, Manchester LC, Reiter RJ, et al. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000;9:137-59
80. Khaldy H, Escames G, Leon J, et al. Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 2000;29:100-7
81. Bergstrom WH, Hakanson DO. Melatonin: The dark force. Adv Pediatr 1998;45:91-106
82. Nohl H, Staniek K. Is melatonin an antioxidant? Wien Klin Wochenschr 1997;109:737-40
83. Lewinska A, Bilinski T, Bartosz G. Limited effectiveness of antioxidants in the protection of yeast defective in antioxidant proteins. Free Radic Res 2004;38:1159-65
84. Abuja PM, Liebmann P, Hayn M, et al. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Lett 1997;413:289-93
85. Yu L, Cherng CF, Chen C. Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice. J Neural Transm 2002;109:1477-90
86. Andreadou I, Iliodromitis EK, Mikros E, et al. Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. Free Radic Biol Med 2004;37:500-10
87. Hemieda FA. Melatonin produced metabolic changes in testis and did not prevent indomethacin-induced testicular lipid peroxidation in adult rat. Indian J Exp Biol 2003;41:220-4
88. Howes RA, Halliday GM, Damian DL. Effect of topical melatonin on ultraviolet radiation-induced suppression of Mantoux reactions in humans. Photodermatol Photoimmunol Photomed 2006;22:267-9
89. Guizar-Sahagun G, Rodriguez-Balderas CA, Franco-Bourland RE, et al. Lack of neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions. Spinal Cord 2009;47:156-60
90. Genade S, Ytrehus K, Lochner A. Melatonin prevents cardioprotection induced by a multi-cycle ischaemic preconditioning protocol in the isolated perfused rat heart. Cardiovasc J S Afr 2006;17:239-44
91. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010;17:2070-95
92. Reiter RJ, Tan DX, Zhou Z, et al. Phytomelatonin: assisting plants to survive and thrive. Molecules 2015;20:7396-437
93. Anderson G, Maes M, Markus RP, Rodriguez M. Ebola virus: melatonin as a readily available treatment option. J Med Virol 2015;87:537-43
94. Ben-Nathan D, Maestroni GJ, Lustig S, Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch Virol 1995;140:223-30
95. San-Miguel B, Crespo I, Vallejo D, et al. Melatonin modulates the autophagic response in acute liver failure induced by the rabbit hemorrhagic disease virus. J Pineal Res 2014;56:313-21
96. Valero N, Nery A, Bonilla E, et al. Antagonistic effect of luzindole in mice treated with melatonin during the infection with the venezuelan equine encephalomyelitis virus. Neurochem Res 2009;34:268-73
97. Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 2015;22(3):R183-204
98. Garcia CP, Lamarque AL, Comba A, et al. Synergistic anti-tumor effects of melatonin and PUFAs from walnuts in a murine mammary adenocarcinoma model. Nutrition 2015;31:570-7
99. Catrina SB, Curca E, Catrina AI, et al. Melatonin shortens the survival rate of Ehrlich ascites-inoculated mice. Neuro Endocrinol Lett 2001;22:432-4
100. Arendt J. Role of the pineal gland and melatonin in seasonal reproductive function in mammals. Oxf Rev Reprod Biol 1986;8:266-320
101. Trivedi AK, Kumar V. Melatonin: an internal signal for daily and seasonal timing. Indian J Exp Biol 2014;52:425-37
102. Reiter RJ, Rosales-Corral SA, Manchester LC, et al. Melatonin in the biliary tract and liver: health implications. Curr Pharm Des 2014;20:4788-801
103. Walters-Laporte E, Furman C, Fouquet S, et al. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. J Cardiovasc Pharmacol 1998;32:582-92
104. Reiter RJ, Tan DX, Cabrera J, D'Arpa D. Melatonin and tryptophan derivatives as free radical scavengers and antioxidants. Adv Exp Med Biol 1999;467:379-87
105. Bai J, Dong L, Song Z, et al. The role of melatonin as an antioxidant in human lens epithelial cells. Free Radic Res 2013;47:635-42
106. Das A, Belagodu A, Reiter RJ, et al. Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res 2008;45:117-24
107. Feng Z, Zhang JT. Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Biol Med 2004;37:1790-801
108. Fischer TW, Zbytek B, Sayre RM, et al. Melatonin increases survival of HaCaT keratinocytes by suppressing UV-induced apoptosis. J Pineal Res 2006;40:18-26
109. Han Y, DeMorrow S, Invernizzi P, et al. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol 2011;301:G623-33
110. Lee JY, Kim JH, Lee DC. Urine melatonin levels are inversely associated with sarcopenia in postmenopausal women. Menopause 2014;21:39-44
111. Martin V, Sainz RM, Antolin I, et al. Several antioxidant pathways are involved in astrocyte protection by melatonin. J Pineal Res 2002;33:204-12
112. Mayo JC, Sainz RM, Antolin I, Rodriguez C. Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage. Brain Res 1999;818:221-7
113. Otsuka M, Kato K, Murai I, et al. Roles of nocturnal melatonin and the pineal gland in modulation of water-immersion restraint stress-induced gastric mucosal lesions in rats. J Pineal Res 2001;30:82-6
114. Pinato L, da Silveira Cruz-Machado S, Franco DG, et al. Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct 2015;220:827-40
115. Romero A, Egea J, Garcia AG, Lopez MG. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J Pineal Res 2010;49:141-8
116. Ryoo YW, Suh SI, Mun KC, et al. The effects of the melatonin on ultraviolet-B irradiated cultured dermal fibroblasts. J Dermatol Sci 2001;27:162-9
117. Sainz RM, Mayo JC, Reiter RJ, et al. Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus. FASEB J 1999;13:1547-56
118. Szarszoi O, Asemu G, Vanecek J, et al. Effects of melatonin on ischemia and reperfusion injury of the rat heart. Cardiovasc Drugs Ther 2001;15:251-7
119. Zasada K, Karbownik-Lewinska M. Comparison of potential protective effects of melatonin and propylthiouracil against lipid peroxidation caused by nitrobenzene in the thyroid gland. Toxicol Ind Health 2013. [Epub ahead of print]
120. Zhao Y, Qi LW, Wang WM, et al. Melatonin improves the survival of cryopreserved callus of Rhodiola crenulata. J Pineal Res 2011;50:83-8
121. Marzullo G. Similar photoperiod-related birth seasonalities among professional baseball players and lesbian women with an opposite seasonality among gay men: Maternal melatonin may affect fetal sexual dimorphism. Psychiatry Res 2014;216:424-31
122. Marzullo G, Boklage CE. Bimodal rhythms of general conceptions and the birth-month phenomenon in schizophrenia, neural tube defects, and laterality: A solstitial hypothesis. Birth Defects Res A Clin Mol Teratol 2011;91:249-57
123. Arnao MB, Hernandez-Ruiz J. Protective effect of melatonin against chlorophyll degradation during the senescence of barley leaves. J Pineal Res 2009;46:58-63
124. Maurizi CP. Choroid plexus portals and a deficiency of melatonin can explain the neuropathology of Alzheimers disease. Med Hypotheses 2010;74:1059-66
125. Kelen D, Robertson NJ. Experimental treatments for hypoxic ischaemic encephalopathy. Early Hum Dev 2010;86:369-77
126. Reiter RJ, Manchester LC, Tan DX. Neurotoxins: free radical mechanisms and melatonin protection. Curr Neuropharmacol 2010;8:194-210
127. Rees S, Harding R, Walker D. The biological basis of injury and neuroprotection in the fetal and neonatal brain. Int J Dev Neurosci 2011;29:551-63
128. Simko F, Paulis L. Antifibrotic effect of melatonin-perspective protection in hypertensive heart disease. Int J Cardiol 2013;168:2876-7
129. Lardone PJ, Alvarez-Sanchez SN, Guerrero JM, Carrillo-Vico A. Melatonin and glucose metabolism: clinical relevance. Curr Pharm Des 2014;20:4841-53
130. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008;44:26-40
131. Jaworek J, Konturek SJ. Hormonal protection in acute pancreatitis by ghrelin, leptin and melatonin. World J Gastroenterol 2014;20:16902-12
132. Jaworek J, Leja-Szpak A. Melatonin influences pancreatic cancerogenesis. Histol Histopathol 2014;29:423-31
133. Jaworek J, Leja-Szpak A, Kot M, et al. The role of melatonin in pancreatic protection: could melatonin be used in the treatment of acute pancreatitis? Curr Pharm Des 2014;20:4834-40
134. Brzozowska I, Strzalka M, Drozdowicz D, et al. Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des 2014;20:4807-15
135. Sapede D, Cau E. The pineal gland from development to function. Curr Top Dev Biol 2013;106:171-215
136. Bonilla E, Valero N, Chacin-Bonilla L, Medina-Leendertz S. Melatonin and viral infections. J Pineal Res 2004;36:73-9
137. Ayoub MA, Levoye A, Delagrange P, Jockers R. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 2004;66:312-21
138. Ayoub MA, Couturier C, Lucas-Meunier E, et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002;277:21522-8
139. Long DJ, Iskander K, Gaikwad A, et al. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002;277:46131-9
140. Brouillette J, Quirion R. Transthyretin: A key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging 2008;29:1721-32
141. Harada S, Tachikawa H, Kawanishi Y. A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia. Psychiatr Genet 2003;13:205-9
142. Okubo T, Harada S, Higuchi S, Matsushita S. Association analyses between polymorphisms of the phase II detoxification enzymes (GSTM1, NQO1, NQO2) and alcohol withdrawal symptoms. Alcohol Clin Exp Res 2003;27:68S-71S
143. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 2001;288:887-92
144. Wang W, Le WD, Pan T, et al. Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J Gerontol A Biol Sci Med Sci 2008;63:127-34
145. Melchiorri D, Ortiz GG, Reiter RJ, et al. Melatonin reduces paraquat-induced genotoxicity in mice. Toxicol Lett 1998;95:103-8
146. Melchiorri D, Reiter RJ, Sewerynek E, et al. Paraquat toxicity and oxidative damage. Reduction by melatonin. Biochem Pharmacol 1996;51:1095-9
147. Melchiorri D, Reiter RJ, Attia AM, et al. Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci 1995;56:83-9
148. Ortiz GG, Reiter RJ, Zuniga G, et al. Genotoxicity of paraquat: micronuclei induced in bone marrow and peripheral blood are inhibited by melatonin. Mutat Res 2000;464:239-45
149. Janda E, Lascala A, Carresi C, et al. Parkinsonian toxin-induced oxidative stress inhibits basal autophagy in astrocytes via NQO2/Quinone Oxidoreductase 2: implications for neuroprotection. Autophagy 2015;11(7):1063-80
150. Giusti P, Lipartiti M, Gusella M, et al. In vitro and in vivo protective effects of melatonin against glutamate oxidative stress and neurotoxicity. Ann N Y Acad Sci 1997;825:79-84
151. Giusti P, Lipartiti M, Franceschini D, et al. Neuroprotection by melatonin from kainate-induced excitotoxicity in rats. FASEB J 1996;10:891-6
152. Giusti P, Franceschini D, Petrone M, et al. In vitro and in vivo protection against kainate-induced excitotoxicity by melatonin. J Pineal Res 1996;20:226-31
153. Giusti P, Gusella M, Lipartiti M, et al. Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-methyl-D-aspartate excitotoxicity. Exp Neurol 1995;131:39-46
154. Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acidinduced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999;128:1754-60
155. Melchiorri D, Reiter RJ, Chen LD, et al. Melatonin affords protection against kainate-induced in vitro lipid peroxidation in brain. Eur J Pharmacol 1996;305:239-42
156. Melchiorri D, Reiter RJ, Sewerynek E, et al. Melatonin reduces kainate-induced lipid peroxidation in homogenates of different brain regions. FASEB J 1995;9:1205-10
157. Manev H, Uz T, Kharlamov A, et al. In vivo protection against kainate-induced apoptosis by the pineal hormone melatonin: effect of exogenous melatonin and circadian rhythm. Restor Neurol Neurosci 1996;9:251-6
158. Smythies J, Galzigna L. The oxidative metabolism of catecholamines in the brain: A review. Biochimica Biophysica Acta 1998;1380:159-62
159. Fu Y, Buryanovskyy L, Zhang Z. Quinone reductase 2 is a catechol quinone reductase. J Biol Chem 2008;283:23829-35
160. Cassagnes LE, Perio P, Ferry G, et al. In cellulo monitoring of quinone reductases actyivity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones. Free Rad Biol Med 2015;in press
161. Graves PR, Kwiek JJ, Fadden P, et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 2002;62:1364-72
162. Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry (Mosc) 2004;43:4538-47
163. Reddy PV, Jensen KC, Mesecar AD, et al. Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2. J Med Chem 2012;55:367-77
164. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-44
165. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63
166. Leung KK, Shilton BH. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT. Biochemistry (Mosc) 2015;54:47-59
167. Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med 2014;66:24-35
168. Kim SJ, Kang HS, Lee JH, et al. Melatonin ameliorates ER stressmediated hepatic steatosis through miR-23a in the liver. Biochem Biophys Res Commun 2015;458:462-9
169. Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 2009;77:1612-20